Trial · NCT03321617
Glutamate Reducing Interventions in Schizophrenia
NCT03321617, Phase 1, Completed, New York State Psychiatric Institute; results first posted 2021-12-01
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Glutamate Reducing Interventions in Schizophrenia. Trials, record NCT03321617. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03321617
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Glutamate Reducing Interventions in Schizophrenia
- NCT number
- NCT03321617
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 16 participants, actual
- Lead sponsor
- New York State Psychiatric Institute
- Conditions
- Clinical High Risk for Psychosis
- Interventions
- Pomaglumetad methionil
- First posted
- 2017-10-25
- Last updated
- 2021-12-01
- Results first posted
- 2021-12-01
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Change in Left Hippocampal CA1 Region Cerebral Blood Volume (CBV) From Baseline to Day 14 | Baseline to 14 days of POMA/placebo | Effect of POMA on left CA1 CBV as measured by percent change from baseline scan (Time 1) to Day 14 scan (Time 2) |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Change in Left Hippocampal CA1 Region Cerebral Blood Volume (CBV) From Baseline to Day 14 | Baseline to 14 days of POMA/placebo | participants who completed both baseline and Day 14 scans | Percent change | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in Left Hippocampal CA1 Region Cerebral Blood Volume (CBV) From Baseline to Day 14 | POMA 40mg BID (80mg) | 0.40684405 | Standard Deviation .63605395 | Percent change | |
| Percent Change in Left Hippocampal CA1 Region Cerebral Blood Volume (CBV) From Baseline to Day 14 | POMA 80mg BID (160 mg) | -0.081559 | Standard Deviation 0.1522939 | Percent change | |
| Percent Change in Left Hippocampal CA1 Region Cerebral Blood Volume (CBV) From Baseline to Day 14 | POMA 120mg BID (240mg) | 0.0219668 | Standard Deviation 0.1484273 | Percent change | |
| Percent Change in Left Hippocampal CA1 Region Cerebral Blood Volume (CBV) From Baseline to Day 14 | POMA 160 mg BID (320 mg) | -0.0269017 | Standard Deviation 0 | Percent change |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | POMA 40mg BID (80mg) | 3 | |
| Overall Study | STARTED | POMA 80mg BID (160 mg) | 3 | |
| Overall Study | STARTED | POMA 120mg BID (240mg) | 2 | |
| Overall Study | STARTED | POMA 160 mg BID (320 mg) | 3 | |
| Overall Study | COMPLETED | POMA 40mg BID (80mg) | 2 | |
| Overall Study | COMPLETED | POMA 80mg BID (160 mg) | 3 | |
| Overall Study | COMPLETED | POMA 120mg BID (240mg) | 2 | |
| Overall Study | COMPLETED | POMA 160 mg BID (320 mg) | 2 | |
| Overall Study | NOT COMPLETED | POMA 40mg BID (80mg) | 1 | |
| Overall Study | NOT COMPLETED | POMA 80mg BID (160 mg) | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events20
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | nausea | Gastrointestinal disorders | POMA 40mg BID (80mg) | 1 | 3 | 1 |
| other | nausea | Gastrointestinal disorders | POMA 80mg BID (160 mg) | 2 | 3 | 2 |
| other | nausea | Gastrointestinal disorders | POMA 120mg BID (240mg) | 1 | 2 | 1 |
| other | nausea | Gastrointestinal disorders | POMA 160 mg BID (320 mg) | 2 | 3 | 2 |
| other | lightheadedness | Nervous system disorders | POMA 40mg BID (80mg) | 0 | 3 | 0 |
| other | lightheadedness | Nervous system disorders | POMA 80mg BID (160 mg) | 0 | 3 | 0 |
| other | lightheadedness | Nervous system disorders | POMA 120mg BID (240mg) | 0 | 2 | 0 |
| other | lightheadedness | Nervous system disorders | POMA 160 mg BID (320 mg) | 1 | 3 | 1 |
| other | dizziness | Nervous system disorders | POMA 40mg BID (80mg) | 0 | 3 | 0 |
| other | dizziness | Nervous system disorders | POMA 80mg BID (160 mg) | 0 | 3 | 0 |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 adverse eventsAdverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | POMA 40mg BID (80mg) | 0 | 3 |
| Total, all-cause mortality | POMA 80mg BID (160 mg) | 0 | 3 |
| Total, all-cause mortality | POMA 120mg BID (240mg) | 0 | 2 |
| Total, all-cause mortality | POMA 160 mg BID (320 mg) | 0 | 3 |
| Total, other adverse events | POMA 40mg BID (80mg) | 1 | 3 |
| Total, other adverse events | POMA 80mg BID (160 mg) | 3 | 3 |
| Total, other adverse events | POMA 120mg BID (240mg) | 1 | 2 |
| Total, other adverse events | POMA 160 mg BID (320 mg) | 2 | 3 |
| Total, serious adverse events | POMA 40mg BID (80mg) | 0 | 3 |
| Total, serious adverse events | POMA 80mg BID (160 mg) | 0 | 3 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R61MH112800 | Glutamate reducing interventions in schizophrenia | SMALL, SCOTT A | COLUMBIA UNIVERSITY HEALTH SCIENCES | NATIONAL INSTITUTE OF MENTAL HEALTH | 2017 to 2018 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03321617
GET https://conductscience.org/api/trials/v1/NCT03321617/registered